Literature DB >> 19838761

Endothelin-B receptors and ventricular arrhythmogenesis in the rat model of acute myocardial infarction.

Dimitrios L Oikonomidis1, Dimitrios G Tsalikakis, Giannis G Baltogiannis, Alexandros T Tzallas, Xanthi Xourgia, Maria G Agelaki, Aikaterini J Megalou, Andreas Fotopoulos, Apostolos Papalois, Zenon S Kyriakides, Theofilos M Kolettis.   

Abstract

The arrhythmogenic effects of endothelin-1 (ET-1) are mediated via ETA-receptors, but the role of ETB-receptors is unclear. We examined the pathophysiologic role of ETB-receptors on ventricular tachyarrhythmias (VT/VF) during myocardial infarction (MI). MI was induced by coronary ligation in two animal groups, namely in wild-type (n = 63) and in ETB-receptor-deficient (n = 61) rats. Using a telemetry recorder, VT/VF episodes were evaluated during phase I (the 1st hour) and phase II (2-24 h) post-MI, with and without prior beta-blockade. Action potential duration at 90% repolarization (APD90) was measured from monophasic epicardial recordings and indices of sympathetic activation were assessed using fast-Fourier analysis of heart rate variability. Serum epinephrine and norepinephrine were measured with radioimmunoassay. MI size was similar in the two groups. There was a marked temporal variation in VT/VF duration; during phase I, it was higher (p = 0.0087) in ETB-deficient (1,519 +/- 421 s) than in wild-type (190 +/- 34 s) rats, but tended (p = 0.086) to be lower in ETB-deficient (4.2 +/- 2.0 s) than in wild-type (27.7 +/- 8.0 s) rats during phase II. Overall, the severity of VT/VF was greater in ETB-deficient rats, evidenced by higher (p = 0.0058) mortality (72.0% vs. 32.1%). There was a temporal variation in heart rate and in the ratio of low- to high-frequency spectra, being higher (<0.001) during phase I, but lower (p < 0.05) during phase II in ETB-deficient rats. Likewise, 1 h post-MI, serum epinephrine (p = 0.025) and norepinephrine (p < 0.0001) were higher in ETB-deficient (4.20 +/- 0.54, 14.24 +/- 1.39 ng/ml) than in wild-type (2.30 +/- 0.59, 5.26 +/- 0.67 ng/ml) rats, respectively. After beta-blockade, VT/VF episodes and mortality were similar in the two groups. The ETB-receptor decreases sympathetic activation and arrhythmogenesis during the early phase of MI, but these effects diminish during evolving MI.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19838761     DOI: 10.1007/s00395-009-0066-7

Source DB:  PubMed          Journal:  Basic Res Cardiol        ISSN: 0300-8428            Impact factor:   17.165


  5 in total

Review 1.  Do endothelin receptor antagonists have an antiarrhythmic potential during acute myocardial infarction? Evidence from experimental studies.

Authors:  Dimitrios L Oikonomidis; Giannis G Baltogiannis; Theofilos M Kolettis
Journal:  J Interv Card Electrophysiol       Date:  2010-06-08       Impact factor: 1.900

2.  Local conduction during acute myocardial infarction in rats: Interplay between central sympathetic activation and endothelin.

Authors:  Theofilos M Kolettis; Marianthi Kontonika; Vassilios La Rocca; Antonios P Vlahos; Giannis G Baltogiannis; Zenon S Kyriakides
Journal:  J Arrhythm       Date:  2016-08-31

3.  Endothelin-1 and norepinephrine overflow from cardiac sympathetic nerve endings in myocardial ischemia.

Authors:  Masashi Tawa; Satoshi Yamamoto; Mamoru Ohkita; Yasuo Matsumura
Journal:  Cardiol Res Pract       Date:  2012-06-25       Impact factor: 1.866

4.  Endothelin-B Receptors and Left Ventricular Dysfunction after Regional versus Global Ischaemia-Reperfusion in Rat Hearts.

Authors:  Sofia-Iris Bibli; Eleni V Toli; Agapi D Vilaeti; Varnavas C Varnavas; Giannis G Baltogiannis; Apostolos Papalois; Zenon S Kyriakides; Theofilos M Kolettis
Journal:  Cardiol Res Pract       Date:  2012-07-12       Impact factor: 1.866

5.  Central Sympathetic Activation and Arrhythmogenesis during Acute Myocardial Infarction: Modulating Effects of Endothelin-B Receptors.

Authors:  Theofilos M Kolettis; Marianthi Kontonika; Eleonora Barka; Evangelos P Daskalopoulos; Giannis G Baltogiannis; Christos Tourmousoglou; Apostolos Papalois; Zenon S Kyriakides
Journal:  Front Cardiovasc Med       Date:  2015-02-23
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.